[Form 4] Cardlytics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Cardlytics, Inc. (CDLX) – Form 4 insider activity for CEO Amit Gupta

On July 1 2025 Mr. Gupta acquired 14,349 common shares through the conversion of restricted stock units (code “M”). The RSUs are part of a previously disclosed 114,796-unit award that vests in eight equal quarterly installments from July 1 2024 through April 1 2026.

On July 2 2025 he sold 6,725 shares at a weighted-average price of $1.7826 solely to cover tax-withholding obligations associated with the vesting event. No other purpose for the sale was indicated.

After the transactions Mr. Gupta directly owns 378,704 common shares and retains 43,049 unvested RSUs. Net of the tax sale, his direct equity stake increased by 7,624 shares.

The activity does not involve new option grants, cash compensation or changes to company fundamentals; it is a routine vesting-and-withholding event that modestly raises the CEO’s long-term exposure to the stock.

Positive

• Net increase of 7,624 shares in CEO’s direct ownership, signalling continued alignment with shareholders.
• 43,049 RSUs remain outstanding, indicating further potential ownership growth as future tranches vest.

Negative

• 6,725 shares sold (though for tax withholding) could still be viewed as insider selling by some investors.
• Transactions highlight low share price range ($1.66–$1.8451), underscoring current market weakness for CDLX.

Insights

Financial Analyst

TL;DR: Routine RSU vesting; small tax sale; CEO’s net holdings rise—neutral signal, minimal market impact.

The filing reflects ordinary-course equity compensation mechanics. The 14,349-share RSU conversion expands Gupta’s direct ownership, aligning management with shareholders. The 6,725-share disposition—explicitly for withholding—reduces the optical negativity normally associated with insider selling. Post-transaction ownership of 378,704 shares plus 43,049 remaining RSUs suggests continued commitment. Given the low dollar value (~$12 k) and absence of operational disclosures, the impact on valuation or sentiment should be negligible.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gupta Amit

(Last) (First) (Middle)

675 PONCE DE LEON AVENUE NE

SUITE 4100

(Street)

ATLANTA GA 30308

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cardlytics, Inc. [ CDLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2025		M		14,349	A	(1)	385,429	D
Common Stock	07/02/2025		S		6,725(2)	D	$1.7826(3)	378,704	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	07/01/2025		M			14,349	(4)	(4)	Common Stock	14,349	$0	43,049	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer.

2. Shares were sold solely to satisfy tax withholding obligations that resulted from the delivery of shares of common stock for RSUs that vested on July 1, 2025. The Reporting Person did not sell shares for any other purpose.

3. The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $1.66 to $1.8451, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3).

4. The RSU award was originally for 114,796 shares. The RSU award vested or will vest in eight equal installments on July 1, 2024, October 1, 2024, January 1, 2025, April 1, 2025, July 1, 2025, October 1, 2025, January 1, 2026 and April 1, 2026, provided that the Reporting Person remains employed by the Issuer on such vesting date.

Remarks:

	/s/ Nick Lynton, Attorney-in-Fact	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CDLX shares did CEO Amit Gupta acquire on July 1 2025?

14,349 common shares were acquired through RSU conversion.

Why were 6,725 CDLX shares sold on July 2 2025?

The filing states the sale was solely to satisfy tax-withholding obligations from the RSU vesting event.

What is Amit Gupta’s current direct ownership in Cardlytics?

After the reported transactions he holds 378,704 common shares plus 43,049 unvested RSUs.

What was the weighted-average sale price of the shares disposed?

The reported weighted average price was $1.7826 per share.

Does the Form 4 indicate any new compensation grants?

No. The filing covers vesting of an existing RSU award; no new grants were disclosed.